T1	intervention 0 12	Levofloxacin
T2	control 68 77	ofloxacin
T4	total-participants 409 412	199
T5	eligibility 425 495	patients hospitalized in our department for treatment of breast cancer
T6	total-participants 556 559	181
T7	iv-bin-abs 585 589	Four
T8	iv-bin-percent 591 593	4%
T9	intervention-participants 602 604	99
T10	outcome 644 660	wound infections
T11	cv-bin-abs 669 670	5
T12	cv-bin-percent 672 674	6%
T13	control-participants 683 685	82
T14	outcome 723 757	median times needed for wound care
T15	iv-cont-median 796 798	13
T16	cv-cont-median 842 844	11
T17	outcome 919 940	Staphylococcus aureus
T18	iv-bin-abs 902 907	three
T19	cv-bin-abs 987 990	two
T3	iv-cont-q1 800 801	9
T20	iv-cont-q3 803 805	16
T21	cv-cont-q1 846 847	9
T22	cv-cont-q3 849 851	16
T23	outcome 1291 1299	toxicity
